2.1. Trial Design and Oversight
HEART, SECONDARY
The study was a prospective, open label, and randomized controlled trial conducted in Wuhan Asia Heart Hospital in China. The study compared the primary and secondary outcomes between patients receiving warfarin therapy who received social app management and those who received routine management. The protocol was designed by a multidisciplinary team that included doctors, biomedical scientists, pharmacists, and nurses. No changes were made to the protocol design, eligibility criteria, or outcome evaluations once the trial started. The protocol was conducted in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. Ethical approval for this study was obtained from the Wuhan Asia Heart Hospital ethical committee (2017-YXKY-B012). The full trial protocol was also registered at the registry of clinical trials (Clinical Trials.gov; 